ClinicalTrials.gg
CompletedNCT01793610Updated Jun 5, 2025Results posted

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

A Phase 2 interventional study of Comparator Dose (40mg) MDMA HCl and Active Dose 2 (100 mg) MDMA HCl in Posttraumatic Stress Disorder, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
17th of 38
29 · median 25
Started
2013
with 1 other
Phase 2
28 of 38
10 open now
Registered
7th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 17th largest by enrollment, is one of 2 that started in 2013, is one of 28 in phase 2, and was the 7th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.

The main questions it aims to answer are:

  • Does MDMA-assisted therapy reduce PTSD symptoms?
  • Is there a difference in PTSD symptoms between the 40 mg, 100 mg, and 125 mg groups?

Researchers will compare two active doses (100 mg and 125 mg) of MDMA-assisted therapy versus a comparator dose of 40 mg MDMA-assisted therapy to determine if there is a reduction in PTSD symptoms.

Participants will undergo three non-drug preparatory sessions, three MDMA-assisted therapy sessions and three non-drug integrative therapy sessions after each MDMA-assisted therapy session.

Read the detailed description

This Phase 2 pilot study is a randomized, double-blind, dose response study to examine the safety and efficacy of MDMA-assisted psychotherapy in 23 subjects with chronic, treatment-resistant PTSD of at least six months duration. This study assessed two active doses of MDMA, active dose 1 (100 mg) and active dose 2 (125 mg), to a comparator dose of MDMA (40 mg) during psychotherapy sessions. The initial dose of MDMA was followed 1.5 to 2.5 hours later by an optional supplemental dose of MDMA that was half the size of the first dose. MDMA was administered orally in two experimental sessions lasting up to eight hours and scheduled three to five weeks apart.

Subjects were prepared for MDMA-assisted psychotherapy in three preparatory sessions prior to the first experimental session, and worked with the same pair of therapists throughout the study. After each experimental session, three integrative sessions were scheduled with the subject, including one integrative session the morning after the experimental session. During integrative sessions, subjects processed and connected their thoughts and feelings about the experience with their therapist team.

Subjects who received the comparator dose (40 mg) were given the option to enroll in Stage 2, where they underwent three open-label MDMA-assisted psychotherapy sessions. 100 mg of MDMA was administered in the first session and therapists determined whether to increase to 125 mg of MDMA for the second and third experimental sessions. People who received 125 mg of MDMA during the first two experimental sessions received the same dose during an open-label third experimental session. People who received 100 mg of MDMA during the first two sessions were able to choose, in consultation with their therapist, to either continue to receive 100 mg in a third session or to increase their dose to 125 mg.

A blinded independent rater (IR) assessed the severity of PTSD symptoms at baseline, one month after the second experimental session (the primary endpoint), two months after the third open-label experimental session, and at equivalent points in Stage 2.

03

Conditions studied

  • Posttraumatic Stress Disorder

Keywords

  • MDMA
  • Posttraumatic stress disorder
  • sleep
  • Depression
  • Safety
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with chronic PTSD for six months or longer.
  • Have a CAPS score showing moderate to severe PTSD symptoms.
  • At least one unsuccessful attempt at treatment for PTSD either with talk therapy or with drugs, or discontinuing treatment because of inability to tolerate psychotherapy or drug therapy.
  • Are at least 18 years old.
  • Must be generally healthy.
  • Are willing to refrain from taking any psychiatric medications during the study period.
  • Willing to follow restrictions and guidelines concerning consumption of food, beverages or nicotine the night before and just prior to each MDMA session.
  • Willing to remain overnight at the study site.
  • Are willing to be driven home after experimental sessions either by a driver they arrange, a taxi, or study personnel.
  • Are willing to be contacted via telephone by study personnel.
  • If of child-bearing age, must have a negative pregnancy and agree to use an effective form of .
  • Must provide a personal contact who is willing to be reached in case of emergency.
  • Agree to let the investigators know within 48 hours of any planned medical interventions.
  • Are proficient in reading and speaking English.
  • Agree to have all psychotherapy sessions recorded.
  • Agree not to participate in any other interventional clinical trials during the course of the study.

Exclusion criteria

Exclusion Criteria:

  • Are pregnant or nursing, or if of child-bearing age and do not use an effective means of .
  • Weigh less than 48 kg.
  • Meet criteria for substance abuse or dependence for any substance in the past 60 days.
  • Have used "Ecstasy" (material represented as containing MDMA) more than five times in the last ten years or at least once within 6 months of the MDMA session.
  • Are unable to give adequate .
  • Upon review of past and current drugs/medication, must not be on or have taken a medication that is exclusionary.
  • Upon review of medical or psychiatric history, must not have any current or past diagnosis that would be considered a risk to participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Active comparator
    Comparator Dose (40 mg) MDMA-assisted therapy

    Participants receive an initial dose of comparator dose midomafetamine HCl (40 mg) during each of two therapy sessions.

    Drug: Comparator Dose (40mg) MDMA HCl · Behavioral: Psychotherapy

  • Experimental
    Active Dose 2 (100 mg) MDMA-assisted therapy

    Participants receive an initial dose of Active Dose 2 midomafetamine HCl (100 mg) during each of two therapy sessions.

    Drug: Active Dose 2 (100 mg) MDMA HCl · Behavioral: Psychotherapy

  • Experimental
    Active Dose 1 (125 mg) MDMA-assisted therapy

    Participants receive an initial dose of Active Dose 1 midomafetamine HCl (125 mg) during each of two therapy sessions.

    Drug: Active Dose 1 (125 mg) MDMA HCl · Behavioral: Psychotherapy

Interventions

  • An initial comparator-dose of 40 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (20 mg).

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA

  • An initial dose of full-dose 100 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (50 mg).

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA

  • An initial dose of full-dose 125 mg midomafetamine HCl orally given at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose (62.5 mg).

    Also known as: 3,4-methylenedioxymethamphetamine, midomafetamine HCl, midomafetamine, MDMA

  • BehavioralPsychotherapy

    Non-directive manualized therapy

    Also known as: Manualized MDMA-assisted psychotherapy

06

What researchers measure

Primary outcomes

  1. Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session

    The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

Secondary outcomes

  1. Change in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session

    The PTSD Diagnostic Scale (PSD) is self-report measure designed to follow DSM-IV criteria for assessing PTSD. It contains 49 items, with responses made on a four-point scale, ranging from 0 ("not at all") to 3 ("five or more times a week"). The PDS consists of a list of 12 potential traumatic events, 12 items addressing elements of the traumatic event, 17 symptom items, and 9 items assessing impact on areas of life function. Items addressing elements of the traumatic event and life function are answered as either present or not present (Yes or No). The 17 items are summed to create a symptom severity score, with higher scores indicating a greater number and/or intensity of PTSD symptoms. The symptom severity score ranges from 0 to 51.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

  2. Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session

    Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

  3. Change in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session

    The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

  4. Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session

    The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

  5. Change in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session

    The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from "never" to "always." The DES-II uses the same items but with responses made on a 10 point scale from "0%" to "100%" of the time. The scale is scored by treating percentages as single digits to produce a total score with higher scores indicating greater severity. The total score ranges from 0 to 100.

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

  6. Change in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session

    The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. PTGI scores on a 6 point scale are: 0 - I did not experience this as a result of my crisis; 1 - I experienced this change to a very small degree as a result of my crisis; 2 - I experienced this change to a small degree as a result of my crisis; 3 - I experienced this change to a moderate degree as a result of my crisis; 4 - I experienced this change to a great degree as a result of my crisis; and 5 - I experienced this change to a very great degree as a result of my crisis. A total score is calculated by summing the responses to all 21 items, each rated on a 6-point scale, with higher scores indicating greater post-traumatic growth

    Time frame: Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)

07

Results

Posted Oct 14, 2020

Participant flow

Candidates were recruited via Internet advertisements and referrals from mental health professionals.

Stage 1 Randomized, Double-blind Period
Participant flow — Stage 1 Randomized, Double-blind Period
MilestoneComparator Dose MDMA (40 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyActive Dose 1 MDMA (125 mg) and Psychotherapy
Started6913
Completed6912
Not completed001
Stage 2 Open-Label Crossover Period
Participant flow — Stage 2 Open-Label Crossover Period
MilestoneComparator Dose MDMA (40 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyActive Dose 1 MDMA (125 mg) and Psychotherapy
Started500
Completed500
Not completed000

Outcome measures

PrimaryChange in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session

The Clinician-Administered PTSD Scale for DSM-IV (CAPS-IV) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-IV. It contains symptom subscales, a CAPS-IV total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA and PsychotherapyActive Dose 2 (100 mg) MDMA and PsychotherapyComparator-dose (40 mg) MDMA and Psychotherapy
Change in Clinician Administered PTSD Scale for DSM-IV (CAPS-IV) Total Severity Score From Baseline to One Month Post 2nd Experimental Session-26.3 ± 29.52-24.4 ± 24.22-11.5 ± 21.21
SecondaryChange in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session

The PTSD Diagnostic Scale (PSD) is self-report measure designed to follow DSM-IV criteria for assessing PTSD. It contains 49 items, with responses made on a four-point scale, ranging from 0 ("not at all") to 3 ("five or more times a week"). The PDS consists of a list of 12 potential traumatic events, 12 items addressing elements of the traumatic event, 17 symptom items, and 9 items assessing impact on areas of life function. Items addressing elements of the traumatic event and life function are answered as either present or not present (Yes or No). The 17 items are summed to create a symptom severity score, with higher scores indicating a greater number and/or intensity of PTSD symptoms. The symptom severity score ranges from 0 to 51.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA and PsychotherapyActive Dose 2 (100 mg) MDMA and PsychotherapyComparator-dose (40 mg) MDMA and Psychotherapy
Change in PTSD Diagnostic Scale (PDS) From Baseline to One Month Post 2nd Experimental Session-11.3 ± 11.26-10.0 ± 10.44-4.2 ± 3.13
SecondaryChange in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session

Validated self-report measure of symptoms of depression. The BDI-II total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depressive symptoms. The scores range from 0 to 63, with higher score indicating greater severity of depressive symptoms.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA and PsychotherapyActive Dose 2 (100 mg) MDMA and PsychotherapyComparator-dose (40 mg) MDMA and Psychotherapy
Change in Beck Depression Inventory II (BDI-II) From Baseline to One Month Post 2nd Experimental Session-11.0 ± 13.68-9.9 ± 13.26-11.5 ± 7.79
SecondaryChange in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session

The Global Assessment of Functioning (GAF) Scale is a numeric scale ranging from 0 through 100 that is used by mental health clinicians and physicians to subjectively rate the social, occupational, and psychological functioning of adults. Higher scores indicate better functioning.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA-assisted TherapyActive Dose 2 (100 mg) MDMA-assisted TherapyComparator Dose (40 mg) MDMA-assisted Therapy
Change in Global Assessment of Functioning (GAF) Total Score From Baseline to One Month Post 2nd Experimental Session0.6 ± 10.572.4 ± 9.631.5 ± 4.59
SecondaryChange in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session

The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances. It is comprised of 18 items that yield seven component scores. Component scores are summed to create a total score. Total scores range from 0 (better) to 21 (worse), with higher scores indicating poor sleep quality.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA and PsychotherapyActive Dose 2 (100 mg) MDMA and PsychotherapyComparator-dose (40 mg) MDMA and Psychotherapy
Change in Pittsburgh Sleep Quality Index (PSQI) From Baseline to One Month Post 2nd Experimental Session-2.0 ± 4.69-3.6 ± 6.19-0.8 ± 2.48
SecondaryChange in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session

The DES-II is a 28-item self-report measure of dissociation, defined as a lack of normal integration of an individual's thoughts, feelings, or experiences into the stream of consciousness or memory. The scale consists of statements describing facets of dissociation. Respondents indicate how often the specific experience happens to them, from "never" to "always." The DES-II uses the same items but with responses made on a 10 point scale from "0%" to "100%" of the time. The scale is scored by treating percentages as single digits to produce a total score with higher scores indicating greater severity. The total score ranges from 0 to 100.

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA-assisted TherapyActive Dose 2 (100 mg) MDMA-assisted TherapyComparator Dose (40 mg) MDMA-assisted Therapy
Change in Dissociative Experiences Scale (DES-II) From Baseline to One Month Post 2nd Experimental Session-5.9 ± 11.98-13.3 ± 15.25-0.2 ± 6.95
SecondaryChange in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session

The PTGI is a 21-item self-report measure of perceived growth or benefits occurring after a traumatic event. It contains five subscales: relationship to others, new possibilities, personal strength, spiritual change, and appreciation of life. PTGI scores on a 6 point scale are: 0 - I did not experience this as a result of my crisis; 1 - I experienced this change to a very small degree as a result of my crisis; 2 - I experienced this change to a small degree as a result of my crisis; 3 - I experienced this change to a moderate degree as a result of my crisis; 4 - I experienced this change to a great degree as a result of my crisis; and 5 - I experienced this change to a very great degree as a result of my crisis. A total score is calculated by summing the responses to all 21 items, each rated on a 6-point scale, with higher scores indicating greater post-traumatic growth

Time frame:
Baseline Enrollment to 1-Month Post 2nd Experimental Session (Stage 1 Primary Endpoint)
Reported as:
Mean · score on a scale
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session
score on a scaleActive Dose 1 (125 mg) MDMA-assisted TherapyActive Dose 2 (100 mg) MDMA-assisted TherapyComparator Dose (40 mg) MDMA-assisted Therapy
Change in Posttraumatic Growth Inventory (PTGI) From Baseline to One Month Post 2nd Experimental Session15.0 ± 19.7116.2 ± 29.473.8 ± 24.65

Adverse events

Collected over All AEs from baseline to long-term follow-up (approximately 18 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1)0/13 (0%)0/13 (0%)8/13 (61.5%)
Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1)0/9 (0%)1/9 (11.1%)6/9 (66.7%)
Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1)0/6 (0%)0/6 (0%)1/6 (16.7%)
Open-Label Session: Active Dose 10/12 (0%)0/12 (0%)5/12 (41.7%)
Open-Label Session: Active Dose 20/9 (0%)1/9 (11.1%)3/9 (33.3%)
Crossover Open-Label Sessions: Comparator Dose0/5 (0%)0/5 (0%)3/5 (60%)
12 Month Follow-up: Active Dose 10/11 (0%)0/11 (0%)2/11 (18.2%)
12 Month Follow-up: Active Dose 20/9 (0%)1/9 (11.1%)1/9 (11.1%)
12 Month Follow-up: Comparator Dose0/5 (0%)0/5 (0%)1/5 (20%)
SRRs: Active Dose 10/13 (0%)0/13 (0%)0/13 (0%)
SRRs: Active Dose 20/9 (0%)0/9 (0%)0/9 (0%)
SRRs: Comparator0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventActive Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1)Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1)Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1)Open-Label Session: Active Dose 1Open-Label Session: Active Dose 2Crossover Open-Label Sessions: Comparator Dose12 Month Follow-up: Active Dose 112 Month Follow-up: Active Dose 212 Month Follow-up: Comparator DoseSRRs: Active Dose 1SRRs: Active Dose 2SRRs: Comparator
Ruptured ovarian cystNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/90/60/120/90/50/111/90/5———
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/130/90/60/121/90/50/110/90/5———
Tibia fractureInjury, poisoning and procedural complications0/131/90/60/120/90/50/110/90/5———
Most frequent other events
Showing 10 of 42
Most frequent other events
EventActive Dose 1 MDMA (125 mg) and Psychotherapy (Stage 1)Active Dose 2 MDMA (100 mg) and Psychotherapy (Stage 1)Comparator-dose MDMA (40 mg) and Psychotherapy (Stage 1)Open-Label Session: Active Dose 1Open-Label Session: Active Dose 2Crossover Open-Label Sessions: Comparator Dose12 Month Follow-up: Active Dose 112 Month Follow-up: Active Dose 212 Month Follow-up: Comparator DoseSRRs: Active Dose 1SRRs: Active Dose 2SRRs: Comparator
AnxietyPsychiatric disorders3/133/90/60/121/90/51/110/91/50/120/95/5
InsomniaGeneral disorders0/130/90/60/120/90/50/110/90/50/120/93/5
HeadacheGeneral disorders0/131/90/60/120/90/50/110/90/50/120/92/5
Difficulty ConcentratingGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
FatigueGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
Jaw Clenching, Tight JawGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
Low moodGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
Need more sleepGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
RuminationsGeneral disorders0/130/90/60/120/90/50/110/90/50/120/92/5
VomitingGastrointestinal disorders3/130/90/60/120/90/50/110/90/50/130/90/6

Baseline characteristics

Intent-to-Treat (ITT)

Age, Continuous
Age, Continuous(years)Active Dose 1 MDMA (125 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyComparator-dose MDMA (40 mg) and PsychotherapyTotal
Mean45.7 ± 15.5339.6 ± 9.840 ± 11.7142.4 ± 12.93
Sex: Female, Male
Sex: Female, Male(Participants)Active Dose 1 MDMA (125 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyComparator-dose MDMA (40 mg) and PsychotherapyTotal
Female86519
Male4318
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active Dose 1 MDMA (125 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyComparator-dose MDMA (40 mg) and PsychotherapyTotal
Hispanic or Latino0101
Not Hispanic or Latino128626
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Active Dose 1 MDMA (125 mg) and PsychotherapyActive Dose 2 MDMA (100 mg) and PsychotherapyComparator-dose MDMA (40 mg) and PsychotherapyTotal
White119525
American Indian Or Alaska Native0011
Other1001
08

Study locations

1 site
  • Offices of Marcela d'Otalora
    Boulder, Colorado 80304, United States
09

References and documents

Publications

  • Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995 Jan;8(1):75-90. doi: 10.1007/BF02105408. PubMed 7712061 ↗
  • Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol. 1984 Nov;40(6):1365-7. doi: 10.1002/1097-4679(198411)40:63.0.co;2-d. PubMed 6511949 ↗
  • Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996 Dec;67(3):588-97. doi: 10.1207/s15327752jpa6703_13. PubMed 8991972 ↗
  • Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2020 Aug;237(8):2485-2497. doi: 10.1007/s00213-020-05548-2. Epub 2020 Jun 4. PubMed 32500209 ↗
  • Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12;10:650. doi: 10.3389/fpsyt.2019.00650. eCollection 2019. PubMed 31572236 ↗
  • Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019 Sep;236(9):2735-2745. doi: 10.1007/s00213-019-05249-5. Epub 2019 May 7. PubMed 31065731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Dec 2015, 30 months.

Results were first posted in Oct 2020, 4 years 10 months after primary completion. A results delay was requested in Mar 2018.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 30 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2013
First posted
Feb 15, 2013
StartActual
May 13, 2013
Primary completionActual
Dec 3, 2015
CompletionActual
Feb 1, 2017
Results delay requested
Mar 7, 2018
Results first posted
Oct 14, 2020
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01793610
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Feb 15, 2013
Start date
May 13, 2013
Primary completion
Dec 3, 2015
Completion
Feb 1, 2017
Results posted
Oct 14, 2020
Last update
Jun 5, 2025

Study contacts

Marcela d'Otalora, MA, LPC
principal investigator · Private Practice

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion